Due to the high PD-L1 expression on numerous cancer cells facilitating immune evasion, the monoclonal-antibody-mediated blockade of the PD-1/PD-L1 axis enhances anti-tumor immunity [31]. This evidence concerns the gene CD274 and cancer.